Key result
The addition of admission venous lactate level to the GRACE 2.0 score significantly improved the prediction of 30-day mortality in STEMI patients treated with primary PCI.
Why the study?
Conventional STEMI risk predictors may be altered by treatment without reflecting microcirculation, prompting investigation into whether venous lactate adds prognostic value to the GRACE 2.0 model.
Does the addition of admission venous lactate level to the GRACE 2.0 score improve the prediction of 30-day all-cause mortality in STEMI patients treated with primary PCI?
Population
323 STEMI patients treated with primary PCI
Comparison
GRACE 2.0 score plus venous lactate level vs GRACE 2.0 score alone
Design
Prospective single-center registry study
Follow-up
30 days
Authors
Loading...
Venous lactate may add prognostic value in STEMI; leaves open whether it improves risk models or changes practice.
Observational (n=323)
No
Does the addition of admission venous lactate level to the GRACE 2.0 score improve the prediction of 30-day all-cause mortality in STEMI patients treated with primary PCI?
Effect estimate: IDI 0.0685 (95% CI 0.0031 to 0.1338)
p-value: p=0.0402
Admission venous lactate level provides independent and additive prognostic value to the GRACE 2.0 score for predicting 30-day mortality in STEMI patients undergoing primary PCI.
Szabó et al. (2022) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=323). Admission venous lactate level vs. GRACE 2.0 score alone was evaluated on 30-day all-cause mortality (IDI 0.0685, 95% CI 0.0031 to 0.1338, p=0.0402). The addition of admission venous lactate level to the GRACE 2.0 score significantly improved the prediction of 30-day mortality in STEMI patients treated with primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: